Factors related to the outcomes of adjuvant capecitabin monotherapy for high-risk stage II colon cancer
Main Article Content
Abstract
The study aimed to evaluate factors related to the outcome of adjuvant capecitabin monotherapy for high-risk stage II colon cancer. We conducted a retrospective study on 96 patients with high-risk stage II colon cancer who underwent radical surgery and adjuvant treatment with capecitabine at K Hospital from 2016 to 2019. The median follow-up time was 60.6 months, the 5-year DFS and OS rates were 89.5% and 91.1%, respectively. Survival decreased gradually according to stage IIA, IIB, IIC (5 years DFS rates were 93.1%, 89.2%, 66.7%, respectively; p = 0.115) (5 years OS rates were 92.1%, 93.6% and 66.7%, respectively; p = 0.05). 5 years DFS, OS rates were worse in the group with vascular and nerve invasion (DFS: 66.7% vs 91%, p = 0.047; OS: 66.7% vs 92.7%, p = 0.014). The more high-risk factors, the worse the prognosis, DFS and OS according to 0, 1, 2 high risk factors were 100%, 95.8%, 71.4% and 100%, 94.7%, 71.4% (p < 0.05). Multivariate analysis showed that stage IIC and neurovascular invasion were 2 independent prognostic factors for OS outcome.
Article Details
Keywords
Capecitabine, adjuvant, colon cancer, risk factors
References
2. Vi Trần Doanh. Nghiên cứu một số yếu tố nguy cơ di căn xa của ung thư đại trực tràng điều trị tại bệnh viện K từ 2003 - 2004. Tạp chí Y học thực hành. 2005;520.
3. Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet. 2007;370(9604):2020-9.
4. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872-7.
5. Zhang C, Yin S, Tan Y, et al. Patient Selection for Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer: A Systematic Review and Meta-Analysis. Am J Clin Oncol. 2020;43(4):279-87.
6. Matsuda C, Ishiguro M, Teramukai S, et al. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer. 2018;96:54-63.
7. Jeon HJ, Woo JH, Lee HY, et al. Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer. J Korean Soc Coloproctol. 2011;27(3):140-6.
8. André T, de Gramont A, Vernerey D, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015;33(35):4176-87.
9. Kumar A, Kennecke HF, Renouf DJ, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer: Outcomes in Stage II Colon Cancer. Cancer. 2015;121(4):527-34.
10. Babcock BD, Aljehani MA, Jabo B, et al. High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal. Ann Surg Oncol. 2018;25(7):1980-5.